The alarming diffusion of multidrug resistant (MDR) bacterial strains requires investigations on non-antibiotic therapies. Amongst them, the use of bacteriophages (phages) as antimicrobial agents, namely phage therapy, is a promising treatment strategy with support by recent successful compassionate treatments in Europe and the U.S.A. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains ofP. aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel (PYO2, DEV, E215 and E217) and two previously characterized (PAK_P1 and PAK_P4) phages was able to lyseP. aeruginosaboth in planktonic liquid cultures and in biofilm. In addition, we showed that the phage cocktail could cure acute respiratory infection in mouse and treat bacteremia in the wax mothGalleria mellonellalarvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to individual phages in destroying biofilms and providing a faster treatment in mice. We also found theGallerialarvae model to be cost-effective for testing clinical strains susceptibility to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.

Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosabiofilms and treats acute infections in two animal models / F. Forti, D.R. Roach, M. Cafora, M.E. Pasini, D.S. Horner, E.V. Fiscarelli, M. Rossitto, L. Cariani, F. Briani, L. Debarbieux, D. Ghisotti. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - 62:6(2018 Jun), pp. e02573-17.1-e02573-17.13. [10.1128/AAC.02573-17]

Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosabiofilms and treats acute infections in two animal models

F. Forti
Primo
;
M. Cafora;M.E. Pasini;D.S. Horner;L. Cariani;F. Briani;D. Ghisotti
2018-06

Abstract

The alarming diffusion of multidrug resistant (MDR) bacterial strains requires investigations on non-antibiotic therapies. Amongst them, the use of bacteriophages (phages) as antimicrobial agents, namely phage therapy, is a promising treatment strategy with support by recent successful compassionate treatments in Europe and the U.S.A. In this work, we combined host range and genomic information to design a 6-phage cocktail killing several clinical strains ofP. aeruginosa, including those collected from Italian cystic fibrosis (CF) patients, and analyzed the cocktail performance. We demonstrated that the cocktail composed of four novel (PYO2, DEV, E215 and E217) and two previously characterized (PAK_P1 and PAK_P4) phages was able to lyseP. aeruginosaboth in planktonic liquid cultures and in biofilm. In addition, we showed that the phage cocktail could cure acute respiratory infection in mouse and treat bacteremia in the wax mothGalleria mellonellalarvae. Furthermore, administration of the cocktail to larvae prior to bacterial infection provided prophylaxis. In this regard, efficiency of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype of the pseudomonal strain. The cocktail was found to be superior to individual phages in destroying biofilms and providing a faster treatment in mice. We also found theGallerialarvae model to be cost-effective for testing clinical strains susceptibility to phages, suggesting that it could be implemented in the frame of developing personalized phage therapies.
Galleria mellonella; Pseudomonas aeruginosa; bacteriophages; cystic fibrosis; phage therapy
Settore BIO/19 - Microbiologia Generale
Settore BIO/18 - Genetica
19-mar-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
AAC.02573-17.full.pdf

accesso aperto

Descrizione: Articolo
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.63 MB
Formato Adobe PDF
2.63 MB Adobe PDF Visualizza/Apri
e02573-17.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/566739
Citazioni
  • ???jsp.display-item.citation.pmc??? 58
  • Scopus 107
  • ???jsp.display-item.citation.isi??? 101
social impact